SCHEMBL6726327

SCHEMBL6726327

O=S(=O)(CF)c1cccc(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.45
KAT6A Q92794 2/20 0.42
MMP2 P08253 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
PGR P06401 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MBTD1 Q05BQ5 1/20 0.39
L3MBTL3 Q96JM7 1/20 0.39
BRD4 O60885 1/20 0.39
WDR5 P61964 1/20 0.39
HSD17B2 P37059 1/20 0.39
EPAS1 Q99814 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
EDNRB P24530 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748405 0.85 CA1 (0.48) CA1CA2CA9MEN1KMT2A
SCHEMBL4251866 0.83 PLCG1 (0.56) ATMKAT6AMMP2PGREGFR
SCHEMBL99072 0.82 PSIP1 (0.56) ATMKAT6AMMP2PGREGFR
SCHEMBL17364184 0.80 ATM (0.45) ATMKAT6AMMP2CA2PGR
SCHEMBL3600024 0.80 ATM (0.49) ATMKAT6AMMP2PGREGFR
SCHEMBL1369921 0.77 CA2 (0.47) ATMKAT6AMMP2CA2EGFR
SCHEMBL29782813 0.77 ATM (0.43) ATMKAT6AMMP2PGREGFR
SCHEMBL263686 0.77 ATM (0.46) ATMKAT6AMMP2HSD17B2L3MBTL1
SCHEMBL20659429 0.77 ATM (0.43) ATMKAT6AMMP2PGREGFR
SCHEMBL17699828 0.77 ATM (0.43) ATMKAT6AMMP2PGREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 ATM 3673/4885KAT6A 3377/4885MMP2 1607/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 ATM 3770/4885KAT6A 3324/4885MMP2 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.